實驗室開放課題

性別 主要研究領(lǐng)域 性別 主要研究領(lǐng)域 52cellcarcinoma,OSCC）80%以上?？谇击[癌目前的治療效BRD4BRD4關(guān)鍵詞(用分號分開，最多5項目組主要成員姓項目組主要成員姓1N3Brd結(jié)構(gòu)域的蛋白(BRDs)1N3Brd結(jié)構(gòu)域的蛋白(BRDs)6，BET（Bromodomainandextraterminal）NUTRNANMC狀細(xì)胞癌（squamouscellcarcinoma,OSCC）狀細(xì)胞癌（squamouscellcarcinoma,OSCC）鑒于口腔鱗癌與NMCBRD4Kouzarides,T.Chromatinmodificationsandtheirfunction.Cell2007,128,693-705.Shogren-Knaak,M.;Ishii,H.;Sun,J.M.;etal.HistoneH4-K16acetylationcontrolschromatinstructureandpro-teininteractions.Science2006,311,844-847.Turner,B.M.Readingsignalsonthenucleosomewithanewnomenclatureformodifiedhistones.Nat.Struct.Mol.Biol.2005,12,110-Dhalluin,C.;Carlson,J.E.;Zeng,L.;etal.Structureandligandofahistoneacetyltransferasebromodomain.Nature1999,399,491-496.FilippakopoulosP.;KnappS.ThebromodomaininteractionFEBSletters2012,586,2692-6.Jacobson,R.H.;Ladurner,A.G.;King,D.S.;etal.Structureandfunctionof6.Jacobson,R.H.;Ladurner,A.G.;King,D.S.;etal.StructureandfunctionofahumanTAFII250doublebromo-domainmodule.Science2000,288,1422-PhelpsMA,etal.Clinicalresponseandpharmacokineticsfromaphase1studyofanactivedosingscheduleofflavopiridolinrelapsedchroniclymphocyticleukemia.Blood.2009;113:2637–2645.FrenchCA,MiyoshiI,AsterJC,etal.BRD4bromodomaingenerearrangementinaggressivecarcinomawithtranslocationt(15;19).AmJPathol.2001;159(6):1987–FrenchCA,etal.BRD4-NUTfusiononcogene:anovelmechanisminaggressivecarcinoma.CancerRes.2003;63:304–307.FrenchCA,etal.BRD-NUToncoproteins:afamilyofcloselyrelatednuclearproteinsthatblockepithelialdifferentiationandmaintainthegrowthofcarcinomacells.Oncogene.2008;27:2237–2242.Filippakopoulos,P.;QiJ.;PicaudS.;etal.SelectiveInhibitionofBromodomains.Nature2010,468,1067-10Westernblot10Westernblot選用舌癌細(xì)胞系Tca3118,通過